Netherlands · Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 774.22 million. The enterprise value is 776.19 million.
| Market Cap | 774.22M |
| Enterprise Value | 776.19M |
Important Dates
The next estimated earnings date is Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 685.15 million shares outstanding. The number of shares has increased by 1.47% in one year.
| Current Share Class | 685.15M |
| Shares Outstanding | 685.15M |
| Shares Change (YoY) | +1.47% |
| Shares Change (QoQ) | +2.60% |
| Owned by Insiders (%) | 2.11% |
| Owned by Institutions (%) | 13.96% |
| Float | 670.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 55.11 |
| PS Ratio | 2.68 |
| PB Ratio | 3.80 |
| P/TBV Ratio | 8.77 |
| P/FCF Ratio | 30.17 |
| P/OCF Ratio | 29.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 31.90, with an EV/FCF ratio of 30.24.
| EV / Earnings | -111.17 |
| EV / Sales | 2.68 |
| EV / EBITDA | 31.90 |
| EV / EBIT | 48.68 |
| EV / FCF | 30.24 |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.54.
| Current Ratio | 2.79 |
| Quick Ratio | 2.04 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | 4.35 |
| Debt / FCF | 4.26 |
| Interest Coverage | 1.91 |
Financial Efficiency
Return on equity (ROE) is -3.70% and return on invested capital (ROIC) is 3.45%.
| Return on Equity (ROE) | -3.70% |
| Return on Assets (ROA) | 2.85% |
| Return on Invested Capital (ROIC) | 3.45% |
| Return on Capital Employed (ROCE) | 5.48% |
| Revenue Per Employee | 716,263 |
| Profits Per Employee | -17,283 |
| Employee Count | 404 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 0.59 |
Taxes
In the past 12 months, Pharming Group has paid 10.21 million in taxes.
| Income Tax | 10.21M |
| Effective Tax Rate | 344.42% |
Stock Price Statistics
The stock price has increased by +46.85% in the last 52 weeks. The beta is 0.56, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +46.85% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 0.96 |
| Relative Strength Index (RSI) | 40.30 |
| Average Volume (20 Days) | 10,870,812 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 289.37 million and -6.98 million in losses. Loss per share was -0.01.
| Revenue | 289.37M |
| Gross Profit | 258.44M |
| Operating Income | 16.73M |
| Pretax Income | 2.97M |
| Net Income | -6.98M |
| EBITDA | 22.45M |
| EBIT | 16.73M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 107.30 million in cash and 109.27 million in debt, giving a net cash position of -1.97 million or -0.00 per share.
| Cash & Cash Equivalents | 107.30M |
| Total Debt | 109.27M |
| Net Cash | -1.97M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 203.98M |
| Book Value Per Share | 0.30 |
| Working Capital | 134.40M |
Cash Flow
In the last 12 months, operating cash flow was 26.44 million and capital expenditures -771,459, giving a free cash flow of 25.67 million.
| Operating Cash Flow | 26.44M |
| Capital Expenditures | -771,459 |
| Free Cash Flow | 25.67M |
| FCF Per Share | 0.04 |
Margins
Gross margin is 89.31%, with operating and profit margins of 5.78% and -2.41%.
| Gross Margin | 89.31% |
| Operating Margin | 5.78% |
| Pretax Margin | 1.02% |
| Profit Margin | -2.41% |
| EBITDA Margin | 7.76% |
| EBIT Margin | 5.78% |
| FCF Margin | 8.87% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.47% |
| Shareholder Yield | -1.47% |
| Earnings Yield | -0.90% |
| FCF Yield | 3.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 2.24 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 5 |